Related Experiment Video

Updated: Jun 3, 2026

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Anthracyclines induce the accumulation of mutant p53 through E2F1-dependent and -independent mechanisms

M Bug1, M Dobbelstein

  • 1Department of Molecular Oncology, Göttingen Center of Molecular Biosciences-GZMB, Ernst Caspari Haus, University of Göttingen, Göttingen, Germany.

Oncogene
|March 29, 2011
PubMed

Insights

Certain cancer drugs increase mutant p53 mRNA and protein, promoting tumor invasion. However, other drugs decrease mutant p53 by boosting WRAP53, enhancing cancer therapy effectiveness.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Pharmacology

Background:

  • Mutant p53 protein accumulation in cancer cells enhances tumor invasion and chemoresistance.
  • Regulation of mutant p53 mRNA levels and the impact of cancer therapy remain poorly understood.
  • Gain-of-function mutations in p53 are common in various cancers.

Purpose of the Study:

  • To investigate how cancer therapies affect mutant p53 mRNA and protein levels.
  • To identify regulatory mechanisms of mutant p53 expression, including the role of transcription factors and antisense transcripts.
  • To explore the therapeutic implications of modulating mutant p53 levels.

Main Methods:

  • Treatment of cancer cells with various chemotherapeutic agents, including anthracyclines (doxorubicin, daunorubicin, epirubicin, idarubicin) and etoposide.
  • Analysis of TP53 and WRAP53 mRNA and protein expression using molecular biology techniques.
  • Investigation of transcription factor E2F1 binding to the TP53 promoter.
  • Assessment of the effect of WRAP53 knockdown and mutant p53 knockdown on chemosensitivity.

Main Results:

  • Anthracyclines like doxorubicin, daunorubicin, and epirubicin increased mutant p53 mRNA and protein levels.
  • E2F1 was found to bind the TP53 promoter and contribute to mutant p53 expression upon genotoxic treatment.
  • Idarubicin and etoposide did not increase p53 mRNA but strongly induced the natural antisense transcript WRAP53.
  • WRAP53, particularly its first exon, localized to the nucleus and reduced mutant p53 levels.
  • Reducing mutant p53 levels via small-interfering RNA enhanced chemosensitivity.

Conclusions:

  • Different chemotherapeutics differentially regulate transcripts from the TP53 locus, leading to opposing effects on mutant p53 levels.
  • Anthracyclines can increase mutant p53, potentially augmenting its gain-of-function and promoting chemoresistance.
  • Idarubicin and etoposide's induction of WRAP53 suggests a mechanism to counteract mutant p53 accumulation.
  • Understanding these differential drug effects is crucial for optimizing cancer therapy and overcoming chemoresistance.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...